郝曉鑫,中國醫(yī)學(xué)科學(xué)院系統(tǒng)醫(yī)學(xué)研究院/蘇州系統(tǒng)醫(yī)學(xué)研究所研究員,北京協(xié)和醫(yī)學(xué)院博士生導(dǎo)師,免疫與炎癥全國重點實驗室PI,國家級青年人才。于上海交通大學(xué)醫(yī)學(xué)院獲得博士學(xué)位(2014-2019),隨后在美國貝勒醫(yī)學(xué)院從事博士后研究(2019-2024)。主持國家自然科學(xué)基金優(yōu)秀青年科學(xué)基金項目(海外)、面上項目,中國醫(yī)學(xué)科學(xué)院創(chuàng)新工程項目等,擔(dān)任中國病理生理學(xué)會第三屆青年工作委員會委員。
      院校引進(jìn)人才,2024年7月全職加入院校。
腫瘤可與機體多器官、多系統(tǒng)互作,引發(fā)系統(tǒng)效應(yīng)促進(jìn)癌癥演進(jìn),骨髓造血改變是其中的關(guān)鍵驅(qū)動力。我們聚焦研究:1)實體瘤造血調(diào)控的機制及干預(yù)策略;2)腫瘤-骨髓相互重塑驅(qū)動轉(zhuǎn)移形成的機制及抑制策略。前期揭示了腫瘤驅(qū)動髓系造血偏倚的底層機制,并發(fā)現(xiàn)腫瘤相關(guān)造血失調(diào)在術(shù)后仍長期存在;發(fā)現(xiàn)腫瘤引發(fā)兩種不同模式的B細(xì)胞發(fā)育異常、損害免疫治療效力。成果發(fā)表在Cell Stem Cell、Nature Cell Biology、Cell Metabolism、Science Advances、JCI、Blood等高水平期刊。
1.Hao X#, Shen Y#, Chen N, Zhang W, Valverde E, Wu L, Chan HL, Xu Z, Yu L, Gao Y, Bado I, Michie LN, Rivas CH, Dominguez LB, Aguirre S, Pingel BC, Wu YH, Liu F, Ding Y, Edwards DG, Liu J, Alexander A, Ueno NT, Hsueh PR, Tu CY, Liu LC, Chen SH, Hung MC, Lim B, Zhang XH*. Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell. 2023,30(5):648-664.e8. (highlighted in Cancer Discov 2023 Vol. 13 Issue 7 Pages 1510)
2.Hao X#, Shen Y#, Liu J, Alexander A, Wu L, Xu Z, Yu L, Gao Y, Liu F, Chan HL, Li CH, Ding Y, Zhang W, Edwards DG, Chen N, Lim B, Zhang XH. Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions. Nat Cell Biol. 2024 Nov;26(11):1971-1983. doi: 10.1038/s41556-024-01508-6.
3.Hao X#, Gu H#, Chen C#, Huang D, Zhao Y, Xie L, Zou Y, Shu HS, Zhang Y, He X, Lai X, Zhang X, Zhou BO, Zhang CC, Chen GQ, Yu Z*, Yang Y*, Zheng J*. Metabolic Imaging Reveals a Unique Preference of Symmetric Cell Division and Homing of Leukemia-Initiating Cells in an Endosteal Niche. Cell Metab. 2019 Apr 2;29(4):950-965.e6.
4.Chen C#, Hao X#, Lai X#, Liu L#, Zhu J#, Shao H, Huang D, Gu H, Zhang T, Yu Z, Xie L, Zhang X, Yang Y, Xu J*, Zhao Y*, Lu Z*, Zheng J*. Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia. Sci Adv. 2021,7(11):eabd6280.
5. Huang D#, Sun G#, Hao X#, He X#, Zheng Z, Chen C, Yu Z, Xie L, Ma S, Liu L, Zhou BO, Cheng H, Zheng J*, Cheng T*. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression. J Clin Invest. 2021,131(1):e138986.